Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 963 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Foot Clear all
Completed Early Phase 1 Interventional

Topical Sildenafil as Pre-Treatment for Hand-Foot Skin Reaction

NCT03229512
View directory record Official record
Conditions
Hand Foot Skin Reaction
Interventions
Sildenafil
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 22, 2026, 5:32 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety Study of Two Repeat Doses of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults

NCT01124565
View directory record Official record
Conditions
Lateral Canthal Lines, Crow's Feet, Facial Wrinkles
Interventions
RT001
Drug
Lead sponsor
Revance Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
3
States / cities
Birmingham, Alabama • San Diego, California • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 17, 2014 · Synced Oct 22, 2026, 5:32 AM EDT
Completed Phase 2 Interventional

Three-Arm Trial of Novel Treatment for Tinea Pedis

NCT03135912
View directory record Official record
Conditions
Tinea Pedis
Interventions
Experimental Drug SESC 01, Placebo, Terbinafine Hydrochloride
Drug
Lead sponsor
South End Skin Care
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Milford, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 22, 2026, 5:32 AM EDT
Completed Not applicable Interventional

A Prosthetic Foot Test-Drive Strategy for Improving Stability in Veterans With Leg Amputations

NCT05473065
View directory record Official record
Conditions
Amputation
Interventions
Multiaxial Prosthetic Foot Emulator, Commercially available prosthetic feet
Device
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
18 Years to 89 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Minneapolis, Minnesota • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 22, 2026, 5:32 AM EDT
Completed Not applicable Interventional

Clinical Study Evaluating Symphony™ Versus Standard of Care in the Treatment of Non-Healing Diabetic Foot Ulcers

NCT06035536
View directory record Official record
Conditions
Diabetic Foot, Diabetic Foot Ulcer, Foot Ulcer, Chronic Foot Ulcer
Interventions
Symphony™ plus Off-loading, Wound Dressing comprising of calcium alginate Fibracol
Device
Lead sponsor
Aroa Biosurgery Limited
Industry
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
11
States / cities
Los Angeles, California • San Francisco, California • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 22, 2026, 5:32 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluating the Foot Touch Framework Model

NCT04699019
View directory record Official record
Conditions
Barefoot Running
Interventions
Four speeds, Foot Strike Pattern
Other
Lead sponsor
Orthocare Innovations, LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Edmonds, Washington
Source: ClinicalTrials.gov public record
Updated Sep 8, 2021 · Synced Oct 22, 2026, 5:32 AM EDT
Completed Phase 2 Interventional

ALGRX 4975 in the Treatment of Patients With Morton's Neuroma

NCT00130962
View directory record Official record
Conditions
Neuroma
Interventions
ALGRX 4975
Drug
Lead sponsor
AlgoRx Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
2
States / cities
Owings Mills, Maryland • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 3, 2005 · Synced Oct 22, 2026, 5:32 AM EDT
Completed Not applicable Interventional

RESTIFFIC™ Foot Wrap Reduces Moderate to Severe Restless Leg Syndrome

NCT02386423
View directory record Official record
Conditions
Restless Leg Syndrome
Interventions
RESTIFFIC™ Brand Pressure Application System
Device
Lead sponsor
Lake Erie Research Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Erie, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 11, 2015 · Synced Oct 22, 2026, 5:32 AM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail

NCT00443898
View directory record Official record
Conditions
Onychomycosis
Interventions
terbinafine, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 75 Years
Enrollment
518 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
20
States / cities
Birmingham, Alabama • San Diego, California • Denver, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated May 3, 2012 · Synced Oct 22, 2026, 5:32 AM EDT
Completed Not applicable Interventional

Non-healing Diabetic Foot Ulcers (DFU) Treated With SoC With or Without NEOX®CORD 1K

NCT02707406
View directory record Official record
Conditions
Diabetic Foot Ulcers
Interventions
NEOX®CORD 1K, standard of care
Other
Lead sponsor
BioTissue Holdings, Inc
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
19
States / cities
Carlsbad, California • Castro Valley, California • Fair Oaks, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2019 · Synced Oct 22, 2026, 5:32 AM EDT
Completed Not applicable Interventional

Comparative Effectiveness of Microprocessor Controlled and Carbon Fiber Prosthetic Feet in Transtibial Amputees

NCT02864693
View directory record Official record
Conditions
Amputation
Interventions
Kinnex, Pacifica LP
Device
Lead sponsor
Ability Prosthetics and Orthotics, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
Hagerstown, Maryland • Charlotte, North Carolina • York, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Oct 22, 2026, 5:32 AM EDT
Completed Phase 4 Interventional

Treatment of Plantar Fasciitis With Dorsiflexion Night Splints and Medial Arch Supports

NCT00222911
View directory record Official record
Conditions
Plantar Fasciitis
Interventions
dorsiflexion night splint, medial arch support
Device
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 20, 2008 · Synced Oct 22, 2026, 5:32 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Dose-Escalation Study of HTX-034 Following Bunionectomy

NCT04398329
View directory record Official record
Conditions
Bunions, Postoperative Pain
Interventions
HTX-034 low dose, HTX-034 high dose, Luer lock applicator, Bupivacaine HCl
Drug · Device
Lead sponsor
Heron Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
4
States / cities
Phoenix, Arizona • Bellaire, Texas • San Antonio, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 22, 2026, 5:32 AM EDT
Completed Not applicable Interventional Results available

Ankle Foot Orthosis Comparative Effect

NCT03901053
View directory record Official record
Conditions
Foot Injuries and Disorders
Interventions
Reaktiv AFO, PhatBrace AFO
Device
Lead sponsor
Jason Wilken
Other
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Iowa City, Iowa • Bethesda, Maryland • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Oct 22, 2026, 5:32 AM EDT
Withdrawn Phase 1 Interventional

Endogenous Progenitors Cell Therapy for Diabetic Foot Ulcers

NCT01353937
View directory record Official record
Conditions
Diabetic Ulcer
Interventions
AMD3100 injection + rhPDGF-BB topical
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
35 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 4, 2016 · Synced Oct 22, 2026, 5:32 AM EDT
Completed Phase 2 Interventional Results available

Placebo-Controlled Evaluation of N1539 Following Bunionectomy Surgery

NCT02540265
View directory record Official record
Conditions
Pain, Post-operative
Interventions
N1539, Intravenous Placebo
Drug
Lead sponsor
Baudax Bio
Industry
Eligibility
18 Years to 75 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Pasadena, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 22, 2026, 5:32 AM EDT
Completed Not applicable Interventional

Shear and Pressure Reducing Insoles for the Diabetic Foot

NCT00499356
View directory record Official record
Conditions
Diabetes, Ulceration, Amputation, Foot Deformity, Neuropathy
Interventions
pressure reducing insole, GlideSoft®
Device
Lead sponsor
Diabetica Solutions Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 11, 2007 · Synced Oct 22, 2026, 5:32 AM EDT
Recruiting Not applicable Interventional

Miro3D Wound Matrix Study for Diabetic Foot Ulcers and Wound Healing

NCT06939686
View directory record Official record
Conditions
Diabetic Foot Ulcers (DFUs), Chronic Wound of the Lower Limb (Leg Ulcer or Foot Ulcer)
Interventions
Miro3D Wound Matrix, Standard of Care (SOC)
Device · Other
Lead sponsor
Reprise Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
3
States / cities
Coconut Creek, Florida • Tamarac, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 22, 2026, 5:32 AM EDT
Completed Phase 3 Interventional Results available

Extension of Phase 3 Gene Therapy for Painful Diabetic Neuropathy

NCT04055090
View directory record Official record
Conditions
Painful Diabetic Neuropathy, Diabetic Neuropathy, Painful
Interventions
Long-Term Follow-Up of Patients who Received Engensis (VM202), Long-Term Follow-Up of Patients who Received Placebo
Genetic · Drug
Lead sponsor
Helixmith Co., Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
14
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Sacramento, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Oct 22, 2026, 5:32 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of the Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis

NCT01290341
View directory record Official record
Conditions
Tinea Pedis
Interventions
NAFT-600 (naftin 2 % gel), Placebo
Drug
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
860 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
23
States / cities
Tucson, Arizona • Encino, California • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2013 · Synced Oct 22, 2026, 5:32 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Comparison of Stainless Steel and Bioabsorbable Screw Fixation of Lisfranc Foot Injuries

NCT00985023
View directory record Official record
Conditions
Unstable Lisfranc Fracture-dislocations of the Midfoot
Interventions
Steel screw fixation of Lisfranc fracture-dislocation., Absorbable screw fixation of Lisfranc fracture-dislocations.
Procedure
Lead sponsor
Rothman Institute Orthopaedics
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2016
U.S. locations
2
States / cities
Media, Pennsylvania • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Oct 22, 2026, 5:32 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of Intramuscular PDA-002 in Subjects With Diabetic Foot Ulcer With and Without PAD.

NCT02264288
View directory record Official record
Conditions
Peripheral Arterial Disease, Diabetic Foot
Interventions
PDA-002, Placebo
Biological · Other
Lead sponsor
Celularity Incorporated
Industry
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
45
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 22, 2026, 5:32 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Effects of a Homeopathic Anti-inflammatory Topical Cream on Ulcers and Neuropathy in the Diabetic Foot

NCT01951859
View directory record Official record
Conditions
Diabetic Neuropathy
Interventions
Neuropathy/Ulcer Homeopathic topical cream
Other
Lead sponsor
Calvary Hospital, Bronx, NY
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 23, 2014 · Synced Oct 22, 2026, 5:32 AM EDT
Not listed Phase 2 Interventional

Clinical Study of ALLO-ASC-SHEET in Subjects With Diabetic Wagner Grade II Foot Ulcers

NCT04497805
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
ALLO-ASC-SHEET
Biological
Lead sponsor
Anterogen Co., Ltd.
Industry
Eligibility
18 Years to 80 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 24, 2023 · Synced Oct 22, 2026, 5:32 AM EDT